Drugs / Naronapride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05621811 | Jan 2023 → Aug 2025 | gastroparesis | Dr. Falk Pharma GmbH | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-04 | Dr. Falk Pharma GmbH | Results Positive results on naronapride in gastroparesis drfalkpharma.com ↗
Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis. |
| 2024-03-27 | Dr. Falk Pharma GmbH | Regulatory FDA clearance of IND application for naronapride drfalkpharma.com ↗
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Dr. Falk Pharma GmbH | We Proceed to Late-Stage Development of Naronapride drfalkpharma.com ↗ |
| 2026-05-04 | Dr. Falk Pharma GmbH | Positive results on naronapride in gastroparesis drfalkpharma.com ↗ |
| 2024-03-27 | Dr. Falk Pharma GmbH | FDA clearance of IND application for naronapride drfalkpharma.com ↗ |
| 2024-02-07 | Dr. Falk Pharma GmbH | Advancing the development of naronapride... drfalkpharma.com ↗ |
| 2023-02-15 | Dr. Falk Pharma GmbH | Initiation of Phase II Study of naronapride in patients with gastroparesis drfalkpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naronapride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05621811 ↗ |
| Action | Activate | “Naronapride is a 5HT-4 agonist” NCT05621811 ↗ |